Drug Trial Radar · NCT03512262
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
Last checked: Nov 20, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
May 3, 2018
Primary completion
Aug 17, 2021
Study completion Sep 8, 2021
Sponsor
- Lead sponsor
- Radius Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
Conditions
- Osteoporosis
- Osteoporosis, Age-Related
- Osteoporosis Localized to Spine
- Age Related Osteoporosis
- Osteoporosis Senile
- Osteoporosis of Vertebrae
Interventions
AbaloparatideDrug
Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
PlaceboDrug
Abaloparatide-matched placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Lumbar Spine BMD at Month 12Time frame: Baseline, Month 12
Locations
34 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Marin Endocrine Care & Research, Inc.
Greenbrae, California
Alta California Medical Group
Simi Valley, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Panorama Orthopedics & Spine Center
Golden, Colorado
MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)
Washington D.C., District of Columbia
Indago Research & Health Center, Inc.
Hialeah, Florida
Baptist Diabetes Associates, Pa
Miami, Florida
Center For Advanced Research & Education
Gainesville, Georgia
Meridian Clinical Research
Savannah, Georgia
Northwestern University
Chicago, Illinois
The University of Chicago
Chicago, Illinois
New Mexico Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico
SUNY Upstate Medical University
Syracuse, New York
PMG Research of Cary, LLC
Cary, North Carolina
PMG Research of Wilmington, LLC
Wilmington, North Carolina
Ohio State University Medical Center
Columbus, Ohio
Altoona Center For Clinical Research
Duncansville, Pennsylvania
Centex Studies, Inc.
Houston, Texas
Centex Studies, Inc
McAllen, Texas
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia
University of Wisconsin Osteoporosis Clinical Research Program
Madison, Wisconsin
Azienda ospedaliera universitaria integrata di verona(AOUI)
Verona, Italy
Azienda ospedaliera universitaria Careggi
Florence, Tuscany, Italy
Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte
Siena, Tuscany, Italy
ClinicMed Daniluk, Nowak Sp.j.
Bialystok, Poland
Centrum Leczenia Osteoporozy Klinika Zdrowej Kosci
Lodz, Poland
ETG Siedlce
Siedlce, Poland
Lubelskie Centrum Diagnostyczne
Świdnik, Poland
NZOZ Nasz Lekarz
Torun, Poland
Synexus Polska Sp z o.o Oddzial we Wroclawiu
Wroclaw, Poland
Krakowskie Centrum Medyczne Sp. z o.o.
Krakow, Lesser Poland Voivodeship, Poland
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, Masovian Voivodeship, Poland
Zdrowie Osteo-Medic s.c. Lidia I Artur Racewicz, Agnieszka I Jerzy Supronik
Bialystok, Podlaskie Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.